Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24700940 | 0.84 | PDK1 (0.40) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL12208867 | 0.83 | ALDH1A1 (0.46) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL25676636 | 0.81 | PDK1 (0.39) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL21207665 | 0.76 | CCR2 (0.42) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL10172721 | 0.75 | PDK1 (0.70) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL25676313 | 0.73 | EPHX1 (0.50) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL25676344 | 0.73 | EPHX1 (0.50) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL25145131 | 0.72 | PKM (0.40) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL25676086 | 0.72 | EPHX1 (0.58) | PDK1PDK2PDK3PDK4PKM | |
| SCHEMBL20377683 | 0.71 | GAA (0.56) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167100-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | NOVARTIS AG (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20230167100-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | NOVARTIS AG (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2021057853-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167100-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | EZH2, BMI1, SUZ12 | PDK1 474/4885PDK2 443/4885PDK3 850/4885 |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, BMI1, EED | PDK1 397/4885PDK2 344/4885PDK3 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.